aortic stenosis – Medxy AI

TAVI Superiority in Women with Aortic Stenosis: New Evidence from the DEDICATE-DZHK6 Trial

By MedXY 03/17/2026

A subgroup analysis of the DEDICATE-DZHK6 trial reveals that TAVI significantly reduces the 1-year risk of death or stroke compared to SAVR in both sexes, with particularly pronounced clinical benefits for women, especially regarding stroke prevention.

Cardiology news

Moderate Mixed Aortic Valve Disease: Why Moderate Severity Carries Severe Risk

By MedXY 03/14/2026

A large-scale multicenter study demonstrates that moderate mixed aortic valve disease (MAVD) carries a mortality risk comparable to severe aortic stenosis when symptoms or left ventricular dysfunction are present, challenging current guideline-based management for these patients.

Cardiology news

Beyond the Gradient: Invasive Exercise Hemodynamics Confirm Discordant Low-Gradient Aortic Stenosis as a High-Risk Phenotype

By MedXY 03/09/2026

A pivotal study using invasive exercise hemodynamics reveals that discordant low-gradient aortic stenosis behaves similarly to high-gradient severe disease, often masking underlying heart failure with preserved ejection fraction (HFpEF) physiology and necessitating earlier clinical intervention.

Cardiology Clinical Updates news

The Hemodynamic Paradox of Valve-in-Valve TAVR: Redefining ‘Optimal’ Gradients and Patient-Prosthesis Mismatch

By MedXY 03/02/2026

This review analyzes new registry data revealing that low discharge gradients (<10 mm Hg) after balloon-expandable ViV-TAVR correlate with reduced LVEF and higher 5-year mortality, challenging conventional hemodynamic success metrics.

Cardiology news

TAVR vs. Surgery in Low-Risk Patients: 7-Year PARTNER 3 Results Confirm Long-Term Parity

By MedXY 02/22/2026

Seven-year data from the PARTNER 3 trial demonstrate that TAVR remains noninferior to surgical aortic-valve replacement in low-risk patients, with comparable rates of death, stroke, and valve durability, supporting TAVR as a sustained alternative to surgery in this population.

Cardiology news

Rethinking Hemodynamics in Aortic Stenosis: The Paradoxical Normal-Flow, Low-Ejection Fraction Phenotype and Post-TAVI Outcomes

By MedXY 01/22/2026

A substudy of the COMPARE-TAVI 1 trial identifies a unique NF-LEF phenotype in 10.7% of aortic stenosis patients. Despite reduced LVEF, these patients maintain normal flow through eccentric remodeling and achieve clinical improvements post-TAVI comparable to those with preserved ejection fractions.

Cardiology news

TAVI vs. SAVR in Women: RHEIA Trial Reveals Distinctive Echocardiographic Advantages for Both Approaches

By MedXY 01/22/2026

The RHEIA trial substudy compares echocardiographic outcomes between TAVI and SAVR in women. While SAVR offers superior LVH regression and lower gradients, TAVI demonstrates significant benefits in preserving right ventricular function and preventing the progression of cardiac damage stages.

Cardiology news

Myval THV Demonstrates 1-Year Noninferiority to Established Transcatheter Heart Valves: Insights from the LANDMARK Trial

By MedXY 12/25/2025

The LANDMARK trial reports that the novel Myval balloon-expandable transcatheter heart valve is clinically noninferior to contemporary SAPIEN and Evolut series at one year, offering comparable safety, hemodynamic performance, and quality-of-life improvements for patients with severe aortic stenosis.

Cardiology news Public Health

Surgical Aortic Valve Replacement Emits Twice the CO2 of TAVR: What This Means for Practice and Policy

By MedXY 11/29/2025

A life cycle assessment found SAVR produces roughly double the carbon footprint of transcatheter aortic valve replacement (TAVR), with postoperative ICU and ward care as the main drivers. Results highlight opportunities to decarbonize cardiac care but do not replace individualized clinical decision-making.

Cardiology news

Dual Pathology No Longer a Dead End: Tafamidis and AVR Improve Survival in Aortic Stenosis with Cardiac Transthyretin Amyloidosis

By MedXY 11/29/2025

In a multinational registry of patients with concomitant aortic stenosis (AS) and transthyretin cardiac amyloidosis (ATTR‑CA), both ATTR‑specific therapy (predominantly tafamidis) and aortic valve replacement (AVR) were independently associated with lower mortality. Combined therapy produced outcomes comparable to lone AS treated with AVR.

Cardiology news

Seven-Year Outcomes of TAVR vs. Surgical Aortic Valve Replacement in Low-Risk Patients: Insights from PARTNER 3

By MedXY 10/31/2025

At 7 years, transcatheter and surgical aortic valve replacement show comparable outcomes including survival, stroke, and valve durability among low-risk patients with severe aortic stenosis, affirming TAVR's long-term efficacy.

Cardiology Clinical Updates news Specialties

Head-to-Head Comparison of SAPIEN 3 and Myval Transcatheter Heart Valves in TAVI: Insights from the COMPARE-TAVI 1 Trial

By MedXY 09/07/2025

The COMPARE-TAVI 1 trial demonstrates non-inferiority of Myval transcatheter heart valves compared to SAPIEN 3 THVs at 1-year post-TAVI for a composite clinical endpoint in severe aortic stenosis patients.

Cardiology Specialties

Three-Year Outcomes of NOTION-2 Trial: Comparing TAVR and SAVR in Younger Low-Risk Patients with Tricuspid or Bicuspid Aortic Stenosis

By MedXY 09/06/2025

The NOTION-2 trial demonstrates comparable three-year outcomes between TAVR and SAVR in low-risk patients aged 60-75 with severe tricuspid or bicuspid aortic stenosis, with low rates of valve deterioration and re-intervention.

Cardiology Medical News news Specialties

TAVI vs SAVR at Low–Intermediate Risk: What the New Individual‑Patient Meta‑Analysis Means for Practice

By MedXY 08/31/2025

A patient‑level meta‑analysis of randomized trials finds transcatheter aortic valve implantation (TAVI) reduces 1‑year risk of death or stroke versus surgical AVR in low– to intermediate‑risk patients—informing patient selection, heart‑team decisions, and follow‑up priorities.

Cardiology Clinical Updates news Specialties

Valve Underexpansion in ACURATE neo2 TAVR: Implications for Clinical Outcomes and Future Directions

By MedXY 08/17/2025

Underexpansion of the ACURATE neo2 valve during TAVR is linked to increased risk of death, stroke, and rehospitalization at one year, suggesting that achieving optimal valve expansion may improve patient outcomes.

Cardiology Neurology news Specialties

Electronic Provider Notification to Facilitate the Recognition and Management of Severe Aortic Stenosis

By MedXY 08/17/2025

This study evaluates the efficacy of electronic provider notifications in increasing aortic valve replacement rates for severe aortic stenosis, improving outcomes in patients.

Cardiology news Specialties

Early TAVR Benefits in Asymptomatic Severe Aortic Stenosis: Insights from Cardiac Biomarker Analysis in the EARLY TAVR Trial

By MedXY 08/17/2025

Cardiac biomarkers NT-proBNP and hs-cTnT predict higher risk in asymptomatic severe aortic stenosis, but early TAVR benefits patients regardless of biomarker levels, with greater relative advantage seen in those with lower biomarker concentrations.

Cardiology Clinical Updates news Specialties

Percutaneous versus Surgical Approaches in Aortic Stenosis with Complex Coronary Disease: TCW Trial Insights

By MedXY 08/02/2025

The TCW trial demonstrates that FFR-guided PCI plus TAVI is non-inferior and even superior to SAVR plus CABG in elderly patients with severe aortic stenosis and complex coronary artery disease.